Sirodusk Tablet contains Sirolimus 1 mg, a potent mTOR inhibitor and immunosuppressant widely used in organ transplant medicine to prevent graft rejection.
This tablet works by modulating the mammalian target of rapamycin (mTOR) pathway, suppressing T-lymphocyte proliferation and reducing immune-mediated damage to transplanted organs. It is ideal for patients requiring targeted immunosuppression under strict medical supervision.
Clinically, Sirodusk Tablet is used in renal, hepatic, and cardiac transplant protocols, often in combination with calcineurin inhibitors and corticosteroids, to maintain graft survival and reduce the risk of rejection episodes.
The tablet ensures accurate dosing, consistent bioavailability, and reliable therapeutic outcomes, making it suitable for hospitals, transplant centers, specialty clinics, and pharmacies managing long-term post-transplant immunosuppressive therapy.